Pronutria, a Cambridge, MA-based developer of a platform to prevent and treat diseases with novel protein nutrients, launched with $10.8m in Series A funding from Flagship Ventures.
Co-founded in 2010 by Flagship VentureLabs, the innovation foundry of Flagship Ventures, and led by Robert Connelly, Pronutria created a platform for identifying protein nutrients from within the human diet that have pharmacological effects.
After two years of development in stealth mode, the company is currently advancing into human clinical testing its lead ProNutrein™ programs to improve muscle, metabolic, and rare diseases.
FinSMEs
22/10/2013